Emmaus Life Sciences Inc (EMMA)

$0.01 0.00 (-13.33%)
Market Cap 958,000.00
Revenue (ttm) 16.65M
Net Income (ttm) -6.45M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -38.74%
Debt to Equity Ratio -0.33
Volume 102,000
Avg Vol 42,764
Day's Range N/A - N/A
Shares Out 63.87M
Stochastic %K 0%
Beta 8.11
Analysts Strong Buy
Price Target $4.00

Company Profile

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Its pipeline products include ELS004, a pharmaceutical grade L-glutamine that is in Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 214 0065
Fax: 310 214 0075
Address:
21250 Hawthorne Boulevard, Suite 800, Torrance, United States
Rage_Against_The_Machine
Rage_Against_The_Machine May. 15 at 8:31 PM
$EMMA Q1 results show the double-edged sword of cost-cutting: Revenue dipped to $2.4M (-4% YoY) as generics bite, but operating loss narrowed to $1M. Cash reserves now at $1.3M - runway getting tight. The math remains brutal: sickle cell specialization vs generic tsunami and negative equity. Survival mode continues. https://www.prnewswire.com/news-releases/emmaus-life-sciences-reports-quarterly-financial-results-302457162.html
0 · Reply
d_risk
d_risk Apr. 14 at 11:02 PM
$EMMA - Emmaus Life Sciences, Inc. - 10K - Updated Risk Factors EMMA faces intensified risks in 2025: widened $9.3M loss, liquidity crunch with debt due and no refinancing, Endari’s U.S. exclusivity expired amid new generic competition and pricing pressure, regulatory setbacks, supply chain issues, and increased dilution and trading volatility risks. #Pharmaceuticals #MarketCompetition #SupplyChain #RegulatoryRisk #FinancialRisk 🟢 Added 🟠 Removed https://d-risk.ai/EMMA/10-K/2025-04-14
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Apr. 14 at 10:27 PM
$EMMA's 2024 results paint a grim picture: revenues plummeted 44% due to inventory mismanagement, now sitting on just $1.4M cash. While cost-cutting helped slightly, the $0.10/share loss and negative ops income reveal structural issues. CEO's 2025 optimism feels like rearranging deck chairs on the Titanic - especially with gene therapies looming. https://www.prnewswire.com/news-releases/emmaus-life-sciences-reports-2024-financial-results-302428165.html
0 · Reply
mhaven2020
mhaven2020 Mar. 14 at 5:03 PM
$EMMA hey! Hello there beautiful! I'm here to play 😉
0 · Reply
insiderbuyingselling
insiderbuyingselling Sep. 18 at 4:09 PM
$EMMA new insider buying: 20000 shares. http://insiderbuyingselling.com/?t=EMMA
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jul. 12 at 2:07 PM
$EMMA Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program
0 · Reply
Ernestpoe
Ernestpoe Jan. 29 at 7:07 PM
$EMMA bought a few shares along with TNBI. Go!
1 · Reply
macroaxis
macroaxis Sep. 8 at 5:01 AM
$QSI - Should I keep QuantumSi and Emmaus Life ( $EMMA ) in the same portfolio? Next fiscal quarter end is on 30th of September 2023 https://www.macroaxis.com/invest/pair-correlation/QSI/EMMA/QuantumSi-vs-Emmaus #portfolio_prospective #better_portfolio #diversify
0 · Reply
EarningsInsider
EarningsInsider Aug. 23 at 1:19 PM
Emmaus Life Sciences, Inc. Files SEC Form 8-K $EMMA https://www.marketbeat.com/stocks/OTCMKTS/EMMA/sec-filings/
0 · Reply
Stock_Titan
Stock_Titan Aug. 23 at 1:00 PM
$EMMA Emmaus Life Sciences Reports Management Changes https://www.stocktitan.net/news/EMMA/emmaus-life-sciences-reports-management-vslpenln1q18.html
0 · Reply
Latest News on EMMA
No data available.
Rage_Against_The_Machine
Rage_Against_The_Machine May. 15 at 8:31 PM
$EMMA Q1 results show the double-edged sword of cost-cutting: Revenue dipped to $2.4M (-4% YoY) as generics bite, but operating loss narrowed to $1M. Cash reserves now at $1.3M - runway getting tight. The math remains brutal: sickle cell specialization vs generic tsunami and negative equity. Survival mode continues. https://www.prnewswire.com/news-releases/emmaus-life-sciences-reports-quarterly-financial-results-302457162.html
0 · Reply
d_risk
d_risk Apr. 14 at 11:02 PM
$EMMA - Emmaus Life Sciences, Inc. - 10K - Updated Risk Factors EMMA faces intensified risks in 2025: widened $9.3M loss, liquidity crunch with debt due and no refinancing, Endari’s U.S. exclusivity expired amid new generic competition and pricing pressure, regulatory setbacks, supply chain issues, and increased dilution and trading volatility risks. #Pharmaceuticals #MarketCompetition #SupplyChain #RegulatoryRisk #FinancialRisk 🟢 Added 🟠 Removed https://d-risk.ai/EMMA/10-K/2025-04-14
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Apr. 14 at 10:27 PM
$EMMA's 2024 results paint a grim picture: revenues plummeted 44% due to inventory mismanagement, now sitting on just $1.4M cash. While cost-cutting helped slightly, the $0.10/share loss and negative ops income reveal structural issues. CEO's 2025 optimism feels like rearranging deck chairs on the Titanic - especially with gene therapies looming. https://www.prnewswire.com/news-releases/emmaus-life-sciences-reports-2024-financial-results-302428165.html
0 · Reply
mhaven2020
mhaven2020 Mar. 14 at 5:03 PM
$EMMA hey! Hello there beautiful! I'm here to play 😉
0 · Reply
insiderbuyingselling
insiderbuyingselling Sep. 18 at 4:09 PM
$EMMA new insider buying: 20000 shares. http://insiderbuyingselling.com/?t=EMMA
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jul. 12 at 2:07 PM
$EMMA Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program
0 · Reply
Ernestpoe
Ernestpoe Jan. 29 at 7:07 PM
$EMMA bought a few shares along with TNBI. Go!
1 · Reply
macroaxis
macroaxis Sep. 8 at 5:01 AM
$QSI - Should I keep QuantumSi and Emmaus Life ( $EMMA ) in the same portfolio? Next fiscal quarter end is on 30th of September 2023 https://www.macroaxis.com/invest/pair-correlation/QSI/EMMA/QuantumSi-vs-Emmaus #portfolio_prospective #better_portfolio #diversify
0 · Reply
EarningsInsider
EarningsInsider Aug. 23 at 1:19 PM
Emmaus Life Sciences, Inc. Files SEC Form 8-K $EMMA https://www.marketbeat.com/stocks/OTCMKTS/EMMA/sec-filings/
0 · Reply
Stock_Titan
Stock_Titan Aug. 23 at 1:00 PM
$EMMA Emmaus Life Sciences Reports Management Changes https://www.stocktitan.net/news/EMMA/emmaus-life-sciences-reports-management-vslpenln1q18.html
0 · Reply
EarningsInsider
EarningsInsider Aug. 14 at 7:34 PM
Emmaus Life Sciences, Inc. Files SEC Form 8-K $EMMA https://www.marketbeat.com/stocks/OTCMKTS/EMMA/sec-filings/
0 · Reply
EarningsInsider
EarningsInsider Aug. 14 at 6:59 PM
Emmaus Life Sciences, Inc. Files SEC Form 10-Q $EMMA https://www.marketbeat.com/stocks/OTCMKTS/EMMA/sec-filings/
0 · Reply